Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 13/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186614 | 0.88 | FBP1 (0.53) | FBP1MCL1PPARDPPARAABCB11 | |
| SCHEMBL5186652 | 0.84 | FBP1 (0.54) | FBP1PPARDPPARAABCB11CYP1A2 | |
| SCHEMBL4113937 | 0.82 | FBP1 (0.54) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5186606 | 0.81 | TDP1 (0.54) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5188264 | 0.81 | MEN1 (0.52) | PPARDPPARACYP3A4PPARGMAPT | |
| SCHEMBL5484169 | 0.81 | FBP1 (0.54) | FBP1PPARDPPARAABCB11CYP1A2 | |
| SCHEMBL5484324 | 0.80 | FBP1 (0.53) | FBP1PPARDPPARAABCB11CYP1A2 | |
| SCHEMBL3385737 | 0.79 | PPARD (0.69) | MCL1PPARDPPARAPPARG | |
| SCHEMBL1549824 | 0.78 | FBP1 (0.58) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL5937515 | 0.78 | FBP1 (0.50) | FBP1PPARDPPARAABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863772-A1 | AMIDE DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007028424-A1 | AMIDE DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20060183754-A1 | Amide bridged piphenyl or biazaphenyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183754-A1 | Amide bridged piphenyl or biazaphenyl derivatives | PPARD, PPARA, PPARG | FBP1 1713/4885MCL1 2431/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.